MEDP vs. ZTS: Medpace vs. Zoetis Stock Comparison

November 11, 2026

How do Medpace (MEDP) and Zoetis (ZTS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Medpace (MEDP) and Zoetis (ZTS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MEDP is classified in Life Sciences Tools & Services while ZTS is classified in Pharmaceuticals.

Company profile comparison for Medpace (MEDP) and Zoetis (ZTS)
Profile Item	MEDP	ZTS
Name	Medpace Holdings, Inc.	Zoetis Inc. Class A Common Stock
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Pharmaceuticals
GICS Sub-Industry	Life Sciences Tools & Services	Pharmaceuticals
Market Capitalization	18.27 billion USD	32.26 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	August 11, 2016	February 1, 2013
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

MEDP

ZTS

GSPC

Medpace (MEDP) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Medpace (MEDP) and Zoetis (ZTS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Medpace (MEDP) and Zoetis (ZTS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Medpace (MEDP) and Zoetis (ZTS)
Metric	MEDP	ZTS
Total Return (1Y)	13.29%	-30.10%
Total Return (3Y, Annualized)	35.26%	-20.42%
Total Return (5Y, Annualized)	24.49%	-16.87%

Risk Profile

Drawdown History

MEDP

ZTS

GSPC

Medpace (MEDP) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Medpace (MEDP) and Zoetis (ZTS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Medpace (MEDP) and Zoetis (ZTS)
Metric	MEDP	ZTS
Volatility (1Y, Annualized)	44.16%	38.23%
Beta (5Y)	1.10	0.66
Max Drawdown (5Y)	-42.87%	-70.45%
Avg. Volume (3M)	258.39K	4.65M

Risk-Adjusted Performance

Risk-Return Positioning

MEDP and ZTS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Medpace (MEDP) and Zoetis (ZTS)
Metric	MEDP	ZTS
Sharpe Ratio (1Y)	0.20	-0.90
Sortino Ratio (1Y)	0.26	-1.10

Profitability

ROE (TTM)

Both companies show strong equity returns, but Medpace (MEDP) at 117.88% is the standout with ROE above its industry range; Zoetis (ZTS) at 57.63% also sits in the top quartile.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

117.88%

MEDP: 117.88%
Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.63%

Max: 109.18%
ZTS: 57.63%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Medpace (MEDP) vs. Zoetis (ZTS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Medpace (MEDP) at 18.24% and Zoetis (ZTS) at 26.41% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.24%

MEDP: 18.24%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.41%

ZTS: 26.41%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Medpace (MEDP) vs. Zoetis (ZTS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Medpace (MEDP) at 23.12% and Zoetis (ZTS) at 38.19% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.12%

Max: 83.12%
MEDP: 23.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.19%

Max: 83.12%
ZTS: 38.19%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Medpace (MEDP) vs. Zoetis (ZTS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Medpace (MEDP) and Zoetis (ZTS)
Metric	MEDP	ZTS
ROE (TTM)	117.88%	57.63%
ROA (TTM)	18.71%	14.87%
Net Margin (TTM)	18.24%	26.41%
Operating Margin (TTM)	23.12%	38.19%
Gross Margin (TTM)	72.24%	71.65%

Growth

Revenue Growth

Both Medpace (MEDP) at 19.97% and Zoetis (ZTS) at 2.28% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Medpace (MEDP) vs. Zoetis (ZTS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Medpace (MEDP) at 20.98% and Zoetis (ZTS) at 10.05% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Medpace (MEDP) vs. Zoetis (ZTS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Medpace (MEDP) and Zoetis (ZTS)
Metric	MEDP	ZTS
Revenue Growth (YoY)	19.97%	2.28%
Revenue Growth (3Y CAGR)	20.12%	5.42%
EPS Growth (YoY)	20.98%	10.05%
EPS Growth (3Y CAGR)	28.04%	10.27%

Financial Strength

Current Ratio (MRQ)

Both Medpace (MEDP) at 0.83 and Zoetis (ZTS) at 2.35 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
MEDP: 0.83
Min: 0.10

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.35

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
ZTS: 2.35
Min: 0.10

Medpace (MEDP) vs. Zoetis (ZTS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Medpace (MEDP) at 0.29 is near its industry mid-range for debt-to-equity ratio, while Zoetis (ZTS) at 2.80 sits above its benchmark range, pointing to a heavier debt load relative to equity.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.29

Max: 1.42
Q3: 0.65
MEDP: 0.29
Median: 0.15
Q1: 0.02
Min: 0.00

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.80

ZTS: 2.80
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Medpace (MEDP) vs. Zoetis (ZTS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Medpace (MEDP) and Zoetis (ZTS)
Metric	MEDP	ZTS
Current Ratio (MRQ)	0.83	2.35
Debt / Equity (MRQ)	0.29	2.80
Net Debt / EBITDA	-0.84	1.92

Dividends

Dividend Yield (TTM)

Medpace (MEDP) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zoetis (ZTS) reports a yield of 2.55%, ranking against industry peers normally.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MEDP: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.55%

ZTS: 2.55%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Medpace (MEDP) vs. Zoetis (ZTS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Medpace (MEDP) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zoetis (ZTS) reports a payout of 35.24%, ranking against industry peers normally.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MEDP: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.24%

ZTS: 35.24%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Medpace (MEDP) vs. Zoetis (ZTS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Medpace (MEDP) and Zoetis (ZTS)
Metric	MEDP	ZTS
Dividend Yield (TTM)	0.00%	2.55%
Dividend Payout Ratio (TTM)	0.00%	35.24%

Valuation

P/E Ratio (TTM)

Both Medpace (MEDP) at 36.26 and Zoetis (ZTS) at 13.50 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.26

Max: 85.34
Q3: 43.46
MEDP: 36.26
Median: 26.69
Q1: 13.30
Min: 0.07

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.50

Max: 85.34
Q3: 43.46
Median: 26.69
ZTS: 13.50
Q1: 13.30
Min: 0.07

Medpace (MEDP) vs. Zoetis (ZTS): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Medpace (MEDP) at 6.44 and Zoetis (ZTS) at 3.40 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.44

Max: 58.18
Q3: 25.77
Median: 7.30
MEDP: 6.44
Q1: 3.01
Min: 0.01

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.40

Max: 58.18
Q3: 25.77
Median: 7.30
ZTS: 3.40
Q1: 3.01
Min: 0.01

Medpace (MEDP) vs. Zoetis (ZTS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both look rich against book: Zoetis (ZTS) at 9.80 sits in the upper P/B ratio quartile, and Medpace (MEDP) at 31.23 prices even higher, above its industry range.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.23

MEDP: 31.23
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.80

Max: 13.53
ZTS: 9.80
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Medpace (MEDP) vs. Zoetis (ZTS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Medpace (MEDP) and Zoetis (ZTS)
Metric	MEDP	ZTS
P/E Ratio (TTM)	36.26	13.50
P/S Ratio (TTM)	6.44	3.40
P/B Ratio (MRQ)	31.23	9.80
Free Cash Flow Yield (TTM)	2.72%	6.36%